United States Generic Drugs Market, By Therapeutic Application [Central Nervous System (CNS), Cardiovascular, Dermatology, Genitourinary (GU)/Harmonal Drugs, Respiratory, Anti-infective, Oncology & Others], Companies (Teva, Mylan N.V., Sandoz, Endo Pharmaceuticals, Lupin Limited, Dr Reddy’s, Sun Pharma, & Others)
United States Generic Drugs Market is projected to exceed USD 210 Billion by 2024. United States Generic Drugs Market is so huge that nearly 80% of dispensing prescriptions accounts generic drugs. According to FDA in the United States 9 out of 10 prescriptions filled are for generic drugs. Most of the physicians and hospitals are now prescribing generic drugs than that of the brand-name drugs. Generic Drugs are those drugs which have same active component as patent drugs in same outline & equal amounts. Generic drugs are also called as Off-Label drugs.
The prime reason for the growth of United States Generic Drugs Market can be attributed to its pricing, on an average generic (Off-Label) drug is around 40-60% cheaper than those of Branded Drugs. However, this price of generic drug further declines, when various generic drug companies target a single approved drug, then market competition results in prices 85% less than the branded drugs. Also, increasing number of drug patent expirations, government initiatives and rising prevalence of chronic diseases are some other factors which are expected to propel the growth of United States Generic Drugs Market in the near future.
Renub Research report titled “United States Generic Drugs Market, By Therapeutic Application [Central Nervous System (CNS), Cardiovascular, Dermatology, Genitourinary (GU)/Harmonal Drugs, Respiratory, Anti-infective, Oncology & Others], Companies (Teva, Mylan N.V., Sandoz, Endo Pharmaceuticals, Lupin Limited, Dr Reddy’s, Sun Pharma, & Others)” provides a complete analysis of US Generic Drugs Market.
Therapeutic Application – Oncology Generic Drug Market is likely to witness a Significant Growth during the Forecast Period
The report studies the market of the following Therapeutic Application segments: Central Nervous System (CNS), Cardiovascular, Dermatology, Genitourinary (GU) / Harmonal Drugs, Respiratory, Anti-infective, Oncology & Others. Central Nervous System (CNS), Cardiovascular, Respiratory and Oncology are some of the segments that will attract the attention of generic drugs market participants.
All companies in this report has been covered with following view points
1. Company Strategy
2. Sales
Companies Analysis
Teva, Mylan, Sandoz, Endo Pharmaceuticals, Lupin Limited, Dr Reddy’s, Sun Pharma are some of the top companies operating in the United States Generic Drug Market; which has been studied thoroughly in the report.
By Therapeutic Application:
The prime reason for the growth of United States Generic Drugs Market can be attributed to its pricing, on an average generic (Off-Label) drug is around 40-60% cheaper than those of Branded Drugs. However, this price of generic drug further declines, when various generic drug companies target a single approved drug, then market competition results in prices 85% less than the branded drugs. Also, increasing number of drug patent expirations, government initiatives and rising prevalence of chronic diseases are some other factors which are expected to propel the growth of United States Generic Drugs Market in the near future.
Renub Research report titled “United States Generic Drugs Market, By Therapeutic Application [Central Nervous System (CNS), Cardiovascular, Dermatology, Genitourinary (GU)/Harmonal Drugs, Respiratory, Anti-infective, Oncology & Others], Companies (Teva, Mylan N.V., Sandoz, Endo Pharmaceuticals, Lupin Limited, Dr Reddy’s, Sun Pharma, & Others)” provides a complete analysis of US Generic Drugs Market.
Therapeutic Application – Oncology Generic Drug Market is likely to witness a Significant Growth during the Forecast Period
The report studies the market of the following Therapeutic Application segments: Central Nervous System (CNS), Cardiovascular, Dermatology, Genitourinary (GU) / Harmonal Drugs, Respiratory, Anti-infective, Oncology & Others. Central Nervous System (CNS), Cardiovascular, Respiratory and Oncology are some of the segments that will attract the attention of generic drugs market participants.
All companies in this report has been covered with following view points
1. Company Strategy
2. Sales
Companies Analysis
Teva, Mylan, Sandoz, Endo Pharmaceuticals, Lupin Limited, Dr Reddy’s, Sun Pharma are some of the top companies operating in the United States Generic Drug Market; which has been studied thoroughly in the report.
By Therapeutic Application:
- Central Nervous System (CNS)
- Cardiovascular
- Dermatology
- Genitourinary (GU)/Harmonal Drugs
- Respiratory
- Anti-infective
- Oncology
- Others
- Teva
- Mylan N.V.
- Sandoz
- Endo Pharmaceuticals
- Lupin Limited
- Dr Reddy’s
- Sun Pharma
- Others
1. EXECUTIVE SUMMARY
2. UNITED STATES PHARMACEUTICAL MARKET
2.1 Branded Pharmaceutical Market
2.2 Generics Pharmaceutical Market
3. UNITED STATES GENERIC DRUGS SAVING
4. MARKET SHARE – UNITED STATES PHARMACEUTICAL
4.1 Branded vs. Generics Drugs
4.2 Branded Generic vs. Unbranded Generic Drug
4.3 Volume Penetration – Generic vs. Branded Drugs
4.4 Therapeutic Application
5. UNITED STATES GENERIC DRUGS MARKET (2010 – 2024)
5.1 Branded Generic Drugs Market
5.2 Unbranded Generic Drugs Market
6. THERAPEUTIC APPLICATION – UNITED STATES GENERIC DRUGS MARKET (2010 – 2024)
6.1 Central Nervous System (CNS)
6.2 Cardiovascular
6.3 Dermatology
6.4 Genitourinary / Hormonal Drugs
6.5 Respiratory
6.6 Anti-infective
6.7 Oncology
6.8 Others
7. TEVA PHARMACEUTICAL INDUSTRIES LTD - COMPANY ANALYSIS
7.1 Product Launch
7.1.1 Point No.
7.1.2 Point No.
7.1.3 Point No.
7.1.4 Point No.
7.1.5 Point No.
7.1.6 Point No.
7.2 Financial Insight
8. MYLAN N.V. - COMPANY ANALYSIS
8.1 Product Launch
8.1.1 Point No.
8.1.2 Point No.
8.1.3 Point No.
8.1.4 Point No.
8.1.5 Point No.
8.1.6 Point No.
8.2 Financial Insight
9. SANDOZ INC. - COMPANY ANALYSIS
9.1 Product Launch
9.1.1 Point No.
9.1.2 Point No.
9.2 Financial Insight
10. ENDO PHARMACEUTICALS - COMPANY ANALYSIS
10.1 Product Launch
10.1.1 Point No.
10.1.2 Point No.
10.1.3 Point No.
10.1.4 Point No.
10.2 Financial Insight
11. LUPIN LIMITED - COMPANY ANALYSIS
11.1 Product Launch
11.1.1 Point No.
11.1.2 Point No.
11.1.3 Point No.
11.1.4 Point No.
11.1.5 Point No.
11.1.6 Point No.
11.1.7 Point No.
11.2 Financial Insight
12. DR REDDY'S - COMPANY ANALYSIS
12.1 Business Portfolio
12.1.1 Point No.
12.1.2 Point No.
12.1.3 Point No.
12.2 Financial Insight
13. SUN PHARMACEUTICAL INDUSTRIES LTD. - COMPANY ANALYSIS
13.1 Product Launch
13.1.1 Point No.
13.1.2 Point No.
13.1.3 Point No.
13.1.4 Point No.
13.2 Financial Insight
14. OTHERS
14.1 Financial Insight
15. GROWTH DRIVER
15.1 Rising Geriatric Population of United States
15.2 Generic Drugs Cost less than Brand Name Drugs
15.3 Rising Incidence of non-communicable Diseases
16. CHALLENGES
16.1 Lack of Regulation & Information
16.2 Long Halt for Expiration of Patent Drug
2. UNITED STATES PHARMACEUTICAL MARKET
2.1 Branded Pharmaceutical Market
2.2 Generics Pharmaceutical Market
3. UNITED STATES GENERIC DRUGS SAVING
4. MARKET SHARE – UNITED STATES PHARMACEUTICAL
4.1 Branded vs. Generics Drugs
4.2 Branded Generic vs. Unbranded Generic Drug
4.3 Volume Penetration – Generic vs. Branded Drugs
4.4 Therapeutic Application
5. UNITED STATES GENERIC DRUGS MARKET (2010 – 2024)
5.1 Branded Generic Drugs Market
5.2 Unbranded Generic Drugs Market
6. THERAPEUTIC APPLICATION – UNITED STATES GENERIC DRUGS MARKET (2010 – 2024)
6.1 Central Nervous System (CNS)
6.2 Cardiovascular
6.3 Dermatology
6.4 Genitourinary / Hormonal Drugs
6.5 Respiratory
6.6 Anti-infective
6.7 Oncology
6.8 Others
7. TEVA PHARMACEUTICAL INDUSTRIES LTD - COMPANY ANALYSIS
7.1 Product Launch
7.1.1 Point No.
7.1.2 Point No.
7.1.3 Point No.
7.1.4 Point No.
7.1.5 Point No.
7.1.6 Point No.
7.2 Financial Insight
8. MYLAN N.V. - COMPANY ANALYSIS
8.1 Product Launch
8.1.1 Point No.
8.1.2 Point No.
8.1.3 Point No.
8.1.4 Point No.
8.1.5 Point No.
8.1.6 Point No.
8.2 Financial Insight
9. SANDOZ INC. - COMPANY ANALYSIS
9.1 Product Launch
9.1.1 Point No.
9.1.2 Point No.
9.2 Financial Insight
10. ENDO PHARMACEUTICALS - COMPANY ANALYSIS
10.1 Product Launch
10.1.1 Point No.
10.1.2 Point No.
10.1.3 Point No.
10.1.4 Point No.
10.2 Financial Insight
11. LUPIN LIMITED - COMPANY ANALYSIS
11.1 Product Launch
11.1.1 Point No.
11.1.2 Point No.
11.1.3 Point No.
11.1.4 Point No.
11.1.5 Point No.
11.1.6 Point No.
11.1.7 Point No.
11.2 Financial Insight
12. DR REDDY'S - COMPANY ANALYSIS
12.1 Business Portfolio
12.1.1 Point No.
12.1.2 Point No.
12.1.3 Point No.
12.2 Financial Insight
13. SUN PHARMACEUTICAL INDUSTRIES LTD. - COMPANY ANALYSIS
13.1 Product Launch
13.1.1 Point No.
13.1.2 Point No.
13.1.3 Point No.
13.1.4 Point No.
13.2 Financial Insight
14. OTHERS
14.1 Financial Insight
15. GROWTH DRIVER
15.1 Rising Geriatric Population of United States
15.2 Generic Drugs Cost less than Brand Name Drugs
15.3 Rising Incidence of non-communicable Diseases
16. CHALLENGES
16.1 Lack of Regulation & Information
16.2 Long Halt for Expiration of Patent Drug
LIST OF FIGURES:
Figure 2-1: US Pharma Market (Billion US$), 2010 – 2017
Figure 2-2: Forecast for US Pharma Market (Billion US$), 2018 – 2024
Figure 2-3: US Branded Pharma Market (Billion US$), 2010 – 2017
Figure 2-4: Forecast for US Branded Pharma Market (Billion US$), 2018 – 2024
Figure 2-5: US Generics Pharma Market (Billion US$), 2010 – 2017
Figure 2-6: Forecast for US Generics Pharma Market (Billion US$), 2018 – 2024
Figure 3-1: Savings from Generics in (Billions US$), - 2016
Figure 3-2: US Generic Saving (Billion US$), 2010 – 2017
Figure 3-3: Forecast for US Generic Saving (Billion US$), 2018 – 2024
Figure 4-1: US Pharmaceutical Market Share (%), 2010 – 2017
Figure 4-2: Forecast for US Pharmaceutical Market Share (%), 2018 – 2024
Figure 4-3: Generic Drug Market Share (%), 2010 – 2017
Figure 4-4: Forecast for Generic Drug Market Share (%), 2018 – 2024
Figure 4-5: US Generic V.S. Branded Drug Volume Penetration (%), 2010 – 2017
Figure 4-6: Forecast for US Generic V.S. Branded Drug Volume Penetration (%), 2018 – 2024
Figure 4-7: US Generic Drugs - By Therapeutic Application Market Share (%), 2010 - 2017
Figure 4-8: Forecast for US Generic Drugs - By Therapeutic Application Market Share (%), 2018 - 2024
Figure 5-1: Branded Generic Drug Market (Billion US$), 2010 – 2017
Figure 5-2: Forecast for Branded Generic Drug Market (Billion US$), 2018 – 2024
Figure 5-3: Unbranded Generic Drug Market (Billion US$), 2010 – 2017
Figure 5-4: Forecast for Unbranded Generic Drug Market (Billion US$), 2018 – 2024
Figure 6-1: Central Nervous System Market (Billion US$), 2010 – 2017
Figure 6-2: Forecast for Central Nervous System Market (Billion US$), 2018 – 2024
Figure 6-3: U.S Incidence of cardiovascular disease by age and sex -2013
Figure 6-4: Cardiovascular Market (Billion US$), 2010 – 2017
Figure 6-5: Forecast for Cardiovascular Market (Billion US$), 2018 – 2024
Figure 6-6: Skin Diseases Prevalence in US – 2013
Figure 6-7: Dermatology Market (Million US$), 2010 – 2017
Figure 6-8: Forecast for Dermatology Market (Million US$), 2018 – 2024
Figure 6-9: Genitourinary/Hormonal Drugs Market (Billion US$), 2010 – 2017
Figure 6-10: Forecast for Genitourinary/Hormonal Drugs Market (Billion US$), 2018 – 2024
Figure 6-11: Respiratory Market (Billion US$), 2010 – 2017
Figure 6-12: Forecast for Respiratory Market (Billion US$), 2018 – 2024
Figure 6-13: Anti-infective Market (Billion US$), 2010 – 2017
Figure 6-14: Forecast for Anti-infective Market (Billion US$), 2018 – 2024
Figure 6-15: Oncology Market (Billion US$), 2010 – 2017
Figure 6-16: Forecast for Oncology Market (Billion US$), 2018 – 2024
Figure 6-17: Others Market (Billion US$), 2010 – 2017
Figure 6-18: Forecast for Others Market (Billion US$), 2018 – 2024
Figure 7-1: Teva – US Generic Drugs Market (Million US$), 2011 – 2017
Figure 7-2: Forecast for Teva – US Generic Drugs Market (Million US$), 2018 – 2024
Figure 8-1: Mylan NV – US Generic Drugs Market (Million US$), 2011 – 2017
Figure 8-2: Forecast for Mylan NV – US Generic Drugs Market (Million US$), 2018 – 2024
Figure 9-1: Sandoz – US Generic Drugs Market (Million US$), 2011 – 2017
Figure 9-2: Forecast for Sandoz – US Generic Drugs Market (Million US$), 2018 – 2024
Figure 10-1: Endo Pharmaceuticals – US Generic Drugs Market (Million US$), 2012 – 2017
Figure 10-2: Forecast for Endo Pharmaceuticals – US Generic Drugs Market (Million US$), 2018 – 2024
Figure 11-1: Lupin Limited – US Generic Drugs Market (Million US$), 2011 – 2017
Figure 11-2: Forecast for Lupin Limited – US Generic Drugs Market (Million US$), 2018 – 2024
Figure 12-1: Dr Reddy’s – North America (US & Canada) Generic Drugs Market (Million US$), 2011 – 2017
Figure 12-2: Forecast for Dr Reddy’s – North America (US & Canada) Generic Drugs Market (Million US$), 2018 – 2024
Figure 13-1: Sun Pharma –US Generic Drugs Market (Million US$), 2011 – 2017
Figure 13-2: Forecast for Sun Pharma –US Generic Drugs Market (Million US$), 2018 – 2024
Figure 14-1: Others - US Generic Drugs Market (Million US$), 2011 – 2017
Figure 14-2: Forecast for Others –US Generic Drugs Market (Million US$), 2018 – 2024
Figure 15-1: United States - Rising Geriatric Population (Million), 2000, 2016 & 2060
Figure 2-1: US Pharma Market (Billion US$), 2010 – 2017
Figure 2-2: Forecast for US Pharma Market (Billion US$), 2018 – 2024
Figure 2-3: US Branded Pharma Market (Billion US$), 2010 – 2017
Figure 2-4: Forecast for US Branded Pharma Market (Billion US$), 2018 – 2024
Figure 2-5: US Generics Pharma Market (Billion US$), 2010 – 2017
Figure 2-6: Forecast for US Generics Pharma Market (Billion US$), 2018 – 2024
Figure 3-1: Savings from Generics in (Billions US$), - 2016
Figure 3-2: US Generic Saving (Billion US$), 2010 – 2017
Figure 3-3: Forecast for US Generic Saving (Billion US$), 2018 – 2024
Figure 4-1: US Pharmaceutical Market Share (%), 2010 – 2017
Figure 4-2: Forecast for US Pharmaceutical Market Share (%), 2018 – 2024
Figure 4-3: Generic Drug Market Share (%), 2010 – 2017
Figure 4-4: Forecast for Generic Drug Market Share (%), 2018 – 2024
Figure 4-5: US Generic V.S. Branded Drug Volume Penetration (%), 2010 – 2017
Figure 4-6: Forecast for US Generic V.S. Branded Drug Volume Penetration (%), 2018 – 2024
Figure 4-7: US Generic Drugs - By Therapeutic Application Market Share (%), 2010 - 2017
Figure 4-8: Forecast for US Generic Drugs - By Therapeutic Application Market Share (%), 2018 - 2024
Figure 5-1: Branded Generic Drug Market (Billion US$), 2010 – 2017
Figure 5-2: Forecast for Branded Generic Drug Market (Billion US$), 2018 – 2024
Figure 5-3: Unbranded Generic Drug Market (Billion US$), 2010 – 2017
Figure 5-4: Forecast for Unbranded Generic Drug Market (Billion US$), 2018 – 2024
Figure 6-1: Central Nervous System Market (Billion US$), 2010 – 2017
Figure 6-2: Forecast for Central Nervous System Market (Billion US$), 2018 – 2024
Figure 6-3: U.S Incidence of cardiovascular disease by age and sex -2013
Figure 6-4: Cardiovascular Market (Billion US$), 2010 – 2017
Figure 6-5: Forecast for Cardiovascular Market (Billion US$), 2018 – 2024
Figure 6-6: Skin Diseases Prevalence in US – 2013
Figure 6-7: Dermatology Market (Million US$), 2010 – 2017
Figure 6-8: Forecast for Dermatology Market (Million US$), 2018 – 2024
Figure 6-9: Genitourinary/Hormonal Drugs Market (Billion US$), 2010 – 2017
Figure 6-10: Forecast for Genitourinary/Hormonal Drugs Market (Billion US$), 2018 – 2024
Figure 6-11: Respiratory Market (Billion US$), 2010 – 2017
Figure 6-12: Forecast for Respiratory Market (Billion US$), 2018 – 2024
Figure 6-13: Anti-infective Market (Billion US$), 2010 – 2017
Figure 6-14: Forecast for Anti-infective Market (Billion US$), 2018 – 2024
Figure 6-15: Oncology Market (Billion US$), 2010 – 2017
Figure 6-16: Forecast for Oncology Market (Billion US$), 2018 – 2024
Figure 6-17: Others Market (Billion US$), 2010 – 2017
Figure 6-18: Forecast for Others Market (Billion US$), 2018 – 2024
Figure 7-1: Teva – US Generic Drugs Market (Million US$), 2011 – 2017
Figure 7-2: Forecast for Teva – US Generic Drugs Market (Million US$), 2018 – 2024
Figure 8-1: Mylan NV – US Generic Drugs Market (Million US$), 2011 – 2017
Figure 8-2: Forecast for Mylan NV – US Generic Drugs Market (Million US$), 2018 – 2024
Figure 9-1: Sandoz – US Generic Drugs Market (Million US$), 2011 – 2017
Figure 9-2: Forecast for Sandoz – US Generic Drugs Market (Million US$), 2018 – 2024
Figure 10-1: Endo Pharmaceuticals – US Generic Drugs Market (Million US$), 2012 – 2017
Figure 10-2: Forecast for Endo Pharmaceuticals – US Generic Drugs Market (Million US$), 2018 – 2024
Figure 11-1: Lupin Limited – US Generic Drugs Market (Million US$), 2011 – 2017
Figure 11-2: Forecast for Lupin Limited – US Generic Drugs Market (Million US$), 2018 – 2024
Figure 12-1: Dr Reddy’s – North America (US & Canada) Generic Drugs Market (Million US$), 2011 – 2017
Figure 12-2: Forecast for Dr Reddy’s – North America (US & Canada) Generic Drugs Market (Million US$), 2018 – 2024
Figure 13-1: Sun Pharma –US Generic Drugs Market (Million US$), 2011 – 2017
Figure 13-2: Forecast for Sun Pharma –US Generic Drugs Market (Million US$), 2018 – 2024
Figure 14-1: Others - US Generic Drugs Market (Million US$), 2011 – 2017
Figure 14-2: Forecast for Others –US Generic Drugs Market (Million US$), 2018 – 2024
Figure 15-1: United States - Rising Geriatric Population (Million), 2000, 2016 & 2060
LIST OF TABLES:
Table 3 1: Top 10 Generic Drugs Ranked by Savings in US - 2016
Table 3 2: Ten Major US State Generic Saving in - 2016
Table 6 1: The Full Burden of 24 Skin Disease categories
Table 3 1: Top 10 Generic Drugs Ranked by Savings in US - 2016
Table 3 2: Ten Major US State Generic Saving in - 2016
Table 6 1: The Full Burden of 24 Skin Disease categories
